Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management

Supporting evidence

• Other supporting evidence

• Methods (PDF 600 KB)

  Published:

  08 February 2023

• Evidence review

• Evidence reviews – February 2023

• A: Patient information and support (PDF 603 KB)

  Published:

  08 February 2023

• B: Pharmacological interventions to reduce progression to dysplasia or cancer (PDF 956 KB)

  Published:

  08 February 2023

• C: Endoscopic surveillance using white light endoscopy (PDF 928 KB)

  Published:

  08 February 2023

• D: Diagnostic accuracy of endoscopic surveillance techniques (PDF 1.13 MB)

  Published:

  08 February 2023

• E: Non-endoscopic surveillance techniques (PDF 927 KB)

  Published:

  08 February 2023

• F: Frequency and duration of endoscopic surveillance (PDF 556 KB)

  Published:

  08 February 2023

• G: Endoscopic and radiological staging techniques (PDF 1.26 MB)

  Published:

  08 February 2023

• H: Endoscopic treatment (high-grade dysplasia and stage 1 adenocarcinoma) (PDF 1.91 MB)

  Published:

  08 February 2023

• I: Endoscopic treatment (low-grade dysplasia and indefinite dysplasia) (PDF 1.15 MB)

  Published:

  08 February 2023

• J: Endoscopic and radiological follow-up after treatment (PDF 732 KB)

  Published:

  08 February 2023

• K: Oesophagectomy versus endoscopic treatment (PDF 986 KB)

  Published:

  08 February 2023

• L: Non-surgical treatment for T1b oesophageal adenocarcinoma (PDF 668 KB)

  Published:

  08 February 2023

• M: Anti-reflux surgery to induce remission of disease or prevent recurrence (PDF 586 KB)

  Published:

  08 February 2023

• N: Anti-reflux surgery to reduce progression to dysplasia or cancer (PDF 676 KB)

  Published:

  08 February 2023